Results 1 to 10 of about 32,127 (239)
Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm [PDF]
Data in Brief, 2023 Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis.
Umi Kalsom Mohamad Yusof +4 more
doaj +2 more sources
The Microenvironment in Myeloproliferative Neoplasms [PDF]
Hematology/Oncology Clinics of North America, 2021 Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN.
Ramanathan, Gajalakshmi +1 more
openaire +4 more sources
Epigenetics in myeloproliferative neoplasms
Frontiers in Oncology, 2023 The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis. Epigenetic changes are the reversible modifications to DNA- and RNA-associated proteins that impact gene activity without changing the DNA sequence ...
Greenfield, Graeme +1 more
openaire +5 more sources
Aetiology of Myeloproliferative Neoplasms [PDF]
Cancers, 2020 Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84, 1.03, and 0.47 per 100,000. Prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low.
Mary Frances McMullin +1 more
openaire +5 more sources
Myeloproliferative neoplasms [PDF]
Clinical Medicine, 2013 The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire +2 more sources
EClinicalMedicine, 2020 Background: Whether inflammation is independently associated with development of JAK2V617F mutation and myeloproliferative neoplasm is not clear. We tested the hypothesis that a loss-of-function polymorphism in IL6R (marked by rs4537545) reduces risk of ...
Kasper Mønsted Pedersen +5 more
doaj +1 more source
The microenvironment in myeloproliferative neoplasm
HemaSphere, 2018 Simón Méndez-Ferrer, Claudia Korn
doaj +2 more sources
EClinicalMedicine, 2020 Background: High cardiovascular comorbidity contributes to excess mortality in patients with myeloproliferative neoplasm, while less is known about respiratory comorbidity and mortality.
Kasper Mønsted Pedersen +5 more
doaj +1 more source
Human Pathology: Case Reports, 2021 We present a rare case of multiple granulocytic sarcoma in a young African woman in blast phase of chronic myeloproliferative neoplasm. Fine needle aspiration cytology of the sarcoma, peripheral blood film and bone marrow aspiration cytology were ...
Ajayi A. Ibijola +2 more
doaj +1 more source
Pathogenesis of myeloproliferative neoplasms [PDF]
Experimental Hematology, 2015 Major progress has been recently made in understanding the molecular pathogenesis of myeloproliferative neoplasms (MPN). Mutations in one of four genes-JAK2, MPL, CALR, and CSF3R-can be found in the vast majority of patients with MPN and represent driver mutations that can induce the MPN phenotype.
Skoda, Radek C. +2 more
openaire +3 more sources